The Orchid Chemicals and Pharmaceuticals and Hospira Inc. deal for the purchase of the former's generic injectable pharmaceuticals business will benefit both parties. While Hospira will gain from Orchid's modern R and D facility, it would strengthen Orchid's business model by providing a steady revenue stream through its long-term API supply agreement with Hospira.
|Sistema Shyam Teleservices||Russian Federation/ Telecommunications||Investment||3,155.2||19.8|
|DLF Assets Ltd||Promoter Group/ Real Estate, Hospitality and Construction||Investment||2,328.3||36|
|Generic Injectable Business of Orchid Chemicals and Pharma||Hospira, Inc./ Pharmaceuticals||Acquisition||1,868.5||100|
|Bangalore International Airport||GVK Power and Infrastructure/ Infrastructure||Investment||686||17|
|NDTV Imagine Ltd||Time Warner Inc./ Media and Entertainment||Acquisition||546.3||76|
|Iron Ore Reserve Mines||Pace Textiles Ltd/ Metals and Mining||Acquisition||260.3||100|
|Snowman Frozen Foods Ltd||International Finance Corporation/ Retail and Consumer Products||Private Equity||248.9||19.99|
|Aerostaff Australia; Gippsland Aeronautics||Mahindra & Mahindra Ltd/ Infrastructure||Acquisition||175.1||75.1|
|Asia Pacific Breweries (Aurangabad) Pvt. Ltd||Heineken NV/ Retail & Consumer Products||Acquisition||174||100|
|Siemens Healthcare||Siemens India Limited/ Healthcare||Acquisition||158.4||100|
— Ernst and Young is a leading M and A advisor in India. While every care has been taken to compile this data, it is based on media reports, company announcements and other secondary research. Any decision on the basis of the above mentioned information should be taken only after professional advice. Business Today or Ernst and Young do not undertake any responsibility in regard to any such decision.
— This list is not a complete list and includes only M and A, private equity and brand sale transactions
— All deals are the biggest deals in the past 30 days as on December 24, 2009